fb5d10ba-36f3-4236-b8fd-7c057db51039
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 43.5811088295688
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.400
- PROTEIN_SECRETION+0.370
- ANDROGEN_RESPONSE+0.320
- TGF_BETA_SIGNALING+0.300
- UV_RESPONSE_DN+0.240
- MTORC1_SIGNALING+0.230
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.200
- KRAS_SIGNALING_UP+0.190
- BILE_ACID_METABOLISM+0.180
- ESTROGEN_RESPONSE_EARLY+0.180
Top 10 suppressed
- MYC_TARGETS_V2-0.370
- E2F_TARGETS-0.270
- ALLOGRAFT_REJECTION-0.260
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.240
- INTERFERON_GAMMA_RESPONSE-0.220
- OXIDATIVE_PHOSPHORYLATION-0.200
- DNA_REPAIR-0.190
- IL6_JAK_STAT3_SIGNALING-0.190
- NOTCH_SIGNALING-0.160
- UV_RESPONSE_UP-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2598057 | fetal | fetal | 0.772 |
| 2 | SRR4296096 | — | cohortA1 | 0.758 |
| 3 | ERR2598079 | fetal | fetal | 0.754 |
| 4 | SRR15069611 | — | — | 0.742 |
| 5 | de751aae-bc7a-4d70-9d06-4417be4facae | — | — | 0.736 |
| 6 | TCGA-CV-7416-01A-11R-2081-07 | — | — | 0.731 |
| 7 | TCGA-AC-A23E-01A-11R-A157-07 | — | A | 0.707 |
| 8 | ERR2598110 | fetal | fetal | 0.690 |
| 9 | MNG121 | — | — | 0.689 |
| 10 | TCGA-AQ-A0Y5-01A-11R-A14M-07 | — | C | 0.681 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.400 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.370 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.320 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.240 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.230 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.190 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.180 | Inavolisib | — uncovered |
| HYPOXIA | 0.160 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.140 | Cobimetinib | — uncovered |
| APICAL_SURFACE | 0.110 | Temsirolimus | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.100 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.090 | Inavolisib | — uncovered |
| COMPLEMENT | 0.080 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.080 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.070 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.070 | Inavolisib | — uncovered |